730 related articles for article (PubMed ID: 19141655)
1. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
Brophy DF; Daniel G; Gitlin M; Mayne TJ
Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
[TBL] [Abstract][Full Text] [Related]
5. Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.
Bacchus S; O'Mara N; Manley H; Fishbane S
Ann Pharmacother; 2009 Nov; 43(11):1857-66. PubMed ID: 19826095
[TBL] [Abstract][Full Text] [Related]
6. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
7. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
8. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
9. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.
Schiller B; Besarab A
Curr Med Res Opin; 2011 Aug; 27(8):1539-50. PubMed ID: 21682552
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
11. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
12. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
13. Hemoglobin level variability: anemia management among variability groups.
Gilbertson DT; Peng Y; Bradbury B; Ebben JP; Collins AJ
Am J Nephrol; 2009; 30(6):491-8. PubMed ID: 19786739
[TBL] [Abstract][Full Text] [Related]
14. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
Coyne DW
Semin Dial; 2008; 21(3):212-6. PubMed ID: 18363603
[TBL] [Abstract][Full Text] [Related]
15. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
Locatelli F; Covic A; Macdougall IC; Wiecek A;
J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
[TBL] [Abstract][Full Text] [Related]
16. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
17. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
18. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
19. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
